NEWTON,
Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that
Kristin Abate, the Company's Vice
President, Accounting, Corporate Controller and Assistant Treasurer
has been appointed the Company's Vice President, Chief Accounting
Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served
as the Company's interim principal financial officer and interim
principal accounting officer since November
6, 2024, has been designated as the Company's principal
accounting officer, effective November 20,
2024. Ms. Abate will continue to serve as the Company's
interim principal financial officer.
Ms. Abate has over 15 years of experience in finance and has
been employed by the Company since July
2019 in a variety of roles with increasing seniority, most
recently as its Vice President, Accounting, Corporate Controller
and Assistant Treasurer. Prior to joining the Company, Ms. Abate
worked in various roles as a public accountant from 2007 to
July 2019 at PricewaterhouseCoopers
LLP. Ms. Abate received a B.S. in Business Administration from
Bryant University and a Masters of
Science in Accountancy from Boston
College and is a certified public accountant.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a
fundamental mechanism of oncogenesis. Karyopharm's lead
compound and firstinclass, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S.
and marketed by the Company in three oncology indications. It
has also received regulatory approvals in various indications in a
growing number of exU.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has
a focused pipeline targeting indications in multiple high
unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large
B-cell lymphoma (DLBCL). For more information about our
people, science and pipeline, please visit www.karyopharm.com,
and follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-announces-the-appointment-of-chief-accounting-officer-302312004.html
SOURCE Karyopharm Therapeutics Inc.